The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
Ó£ÌÒÊÓƵ appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.
The pledge is part of our mission to code cells for novel cures and to be a purpose led company.
Funding raised to accelerate and expand cell therapy pipeline.
Three world leaders in science and entrepreneurship appointed to Ó£ÌÒÊÓƵ's Board of Directors.
This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.
Press release announcing appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer.
Ó£ÌÒÊÓƵ joins forces with London institute of mathematical sciences to find the ‘operating system of life’.
Ó£ÌÒÊÓƵ closes series A $41.5 million funding.